# Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer

> **NCT03947151** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 8 (actual)

## Conditions studied

- Invasive Ductal Breast Carcinoma

## Interventions

- **DRUG:** Degarelix injection(s)

## Key facts

- **NCT ID:** NCT03947151
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-28
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-08-30
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947151, "Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03947151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*